Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
Bernadett Szabados, Mark Kockx, Zoe J. Assaf, et al.
European Urology (2022) Vol. 82, Iss. 2, pp. 212-222
Open Access | Times Cited: 118

Showing 1-25 of 118 citing articles:

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
J. Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
European Urology (2023) Vol. 85, Iss. 1, pp. 17-31
Open Access | Times Cited: 321
Practical recommendations for using ctDNA in clinical decision making
Stacey A. Cohen, Minetta C. Liu, Alexey Aleshin
Nature (2023) Vol. 619, Iss. 7969, pp. 259-268
Closed Access | Times Cited: 82
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Thomas Powles, James W.F. Catto, Matthew D. Galsky, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 51
Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma
Iver Nordentoft, Sia V. Lindskrog, Karin Birkenkamp‐Demtröder, et al.
European Urology (2024) Vol. 86, Iss. 4, pp. 301-311
Open Access | Times Cited: 16
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 23, pp. 5107-5114
Open Access | Times Cited: 65
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Jeroen van Dorp, Christodoulos Pipinikas, Britt B. M. Suelmann, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 588-592
Closed Access | Times Cited: 39
Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection
Joshua J. Meeks, Peter C. Black, Matthew D. Galsky, et al.
European Urology (2023) Vol. 84, Iss. 5, pp. 473-483
Open Access | Times Cited: 36
Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities
Belén Caramelo, Sladjana Zagorac, Sonia Corral, et al.
European Urology Oncology (2023) Vol. 6, Iss. 4, pp. 366-375
Open Access | Times Cited: 26
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review
Emanuele Crupi, Tiago Costa de Pádua, Laura Marandino, et al.
European Urology Oncology (2023) Vol. 7, Iss. 1, pp. 44-52
Closed Access | Times Cited: 26
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
Sia V. Lindskrog, Karin Birkenkamp‐Demtröder, Iver Nordentoft, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 23, pp. 4797-4807
Open Access | Times Cited: 26
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17
Richard Cathomas, Sacha I. Rothschild, Stefanie Hayoz, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 33, pp. 5131-5139
Open Access | Times Cited: 23
Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures
Ying Dong, Xiaoqing Wu, Chaojie Xu, et al.
Aging (2024)
Open Access | Times Cited: 14
Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy
Reuben Ben‐David, Neeraja Tillu, Shivaram Cumarasamy, et al.
European Urology Oncology (2024) Vol. 7, Iss. 5, pp. 1105-1112
Closed Access | Times Cited: 13
Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer
Reuben Ben‐David, Matthew D. Galsky, John P. Sfakianos
Trends in Molecular Medicine (2024) Vol. 30, Iss. 7, pp. 686-697
Closed Access | Times Cited: 8
Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma
Joaquim Bellmunt, Brian M. Russell, Bernadett Szabados, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 2
Closed Access | Times Cited: 1
Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder
Lucas Motta Martinez, Letícia Carina Ribeiro, Roberto Guidi, et al.
Current Oncology Reports (2025)
Closed Access | Times Cited: 1
Recent Advances in Immunotherapy for Bladder Cancer Treatment
Khaled A Alqarni
Cureus (2025)
Open Access | Times Cited: 1
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
Xavier García del Muro, Begoña P. Valderrama, Ana Medina, et al.
Clinical Cancer Research (2025) Vol. 31, Iss. 4, pp. 659-666
Closed Access | Times Cited: 1
Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: a systematic review and meta-analysis
Xindong Gao, Wenqiang Qi, Junxian Li, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Improving Urothelial Carcinoma Outcomes: The Powerful Combination of Neoadjuvant and Adjuvant Chemotherapy in the Perioperative Period
Jincong Li, Yuxuan Song, Rui Chen, et al.
Annals of Surgical Oncology (2025)
Closed Access | Times Cited: 1
Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment
Yuxuan Song, Yun Peng, Caipeng Qin, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 9, pp. e006643-e006643
Open Access | Times Cited: 19
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Francesco Massari, Matteo Santoni, Hideki Takeshita, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 6
Open Access | Times Cited: 7
Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient
Gregory Hemenway, Jonathan F. Anker, Paul Riviere, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
Ying‐Chun Shen, Tsung‐Hao Liu, Alan Nicholas, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 34, pp. 4060-4070
Closed Access | Times Cited: 6
Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer
Aleksandra Semeniuk-Wojtaś, Karolina Poddębniak-Strama, Magdalena Modzelewska, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 1971-1989
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top